

August 12, 2026

To Shareholders,

Company Name: Renascience Inc.
Representative: Toshio Miyata, Chairman and CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

Notice Regarding Withdrawal from XPRIZE Healthspan

We participated in the "XPRIZE Healthspan" competition and conducted a human semi-final trial (as disclosed in the "Preliminary Results of the XPRIZE Healthspan Semi-Final Clinical Trial" dated May 14, 2026). Although our team was recognized as an eligible finalist candidate and engaged in discussions regarding specific participation terms, we have decided not to proceed with the competition for the following reasons:

- ① While the XPRIZE Healthspan evaluation committee rated our semi-final trial results as "Excellent," we were excluded from the award recipients (Top 10) because the treatment involves an "unapproved drug" in the context of anti-aging and longevity, and we consider that it differs from the treatments (existing therapies) that are the primary focus of this competition.
- ② There were concerns that the contractual terms for continuing as a finalist could negatively impact our business operations (including terms regarding data ownership and licensing, a 10-year contractual period, and XPRIZE's potential future use for research and commercial purposes).
- ③ Given the advantages of RS5614 as a novel pharmaceutical ingredient (oral medication), we consider that participation in XPRIZE Healthspan would not necessarily lead to the maximization of our future business value.

Although we are withdrawing from this competition, our policy of actively pursuing research and business operations in the fields of anti-aging and longevity remains unchanged. As the semi-final trial results were highly favorable, we plan to conduct a large-scale clinical trial to further substantiate and build upon those findings. We remain fully committed to developing a pharmaceutical product with the potential to prevent and treat various age-related diseases by ameliorating the aging environment, eliminating senescent cells, and reversing biological age through the improvement of various aging-related pathologies.

We are currently assessing the impact on our financial results for the fiscal year ending March 31, 2027. We will promptly disclose any further information that requires public announcement.